您的购物车当前为空
Casein Kinase II Inhibitor IV 是一种小分子诱导剂,可诱导表皮角质形成细胞分化。
Casein Kinase II Inhibitor IV 是一种小分子诱导剂,可诱导表皮角质形成细胞分化。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 598 | 现货 | |
| 5 mg | ¥ 1,730 | 现货 | |
| 10 mg | ¥ 2,560 | 现货 | |
| 25 mg | ¥ 3,970 | 现货 | |
| 50 mg | ¥ 5,560 | 现货 | |
| 100 mg | ¥ 7,380 | 现货 | |
| 200 mg | ¥ 9,950 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,690 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
该分子属于定制产品。TargetMol拥有优秀的合成团队,经验和能力,可以为您提供高性价比的产品。 如您有任何问题,欢迎咨询,我们将竭诚为您服务。
| 产品描述 | Casein kinase II inhibitor IV is an effective small molecule inducer, which can be used to induce epidermal keratinocyte differentiation. |
| 体外活性 | Treatment of human epidermal keratinocytes (NHEKs) with Casein Kinase II Inhibitor IV leads to an increase in the early differentiation markers keratins 1 and 10 at 48 h. Increased levels of IVL and TGM are observed in cells treated with Casein Kinase II Inhibitor IV at 72 h and persisted at 96 h. In addition, treated with Casein Kinase II Inhibitor IV expresses loricrin, a terminal differentiation marker, at later time points. Similar results are observed by messenger RNA (mRNA) expression analysis of NHEKs treated with Casein Kinase II Inhibitor IV. At early time points (12 and 24 h), treatment with Casein Kinase II Inhibitor IV leads to the upregulation of keratinocyte early differentiation marker genes, including keratin 1 (5.4-fold) and keratin 10 (5.4-fold). Terminal differentiation marker genes, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), are upregulated at late time points (36 and 48 h). |
| 分子量 | 429.47 |
| 分子式 | C24H23N5O3 |
| CAS No. | 863598-09-8 |
| Smiles | COc1cc(Nc2ncc3ccn(-c4cccc(CCC#N)c4)c3n2)cc(OC)c1OC |
| 密度 | 1.25 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 70 mg/mL (162.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.66 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多